Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:49 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2329–2352 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Diabetes Mellitus, Type 1, Hypoglycemia
Interventions: Vigilant Diabetes Management Application; Device
Lead sponsor: InSpark Technologies, Inc.; Industry
Eligibility: 11 Years to 74 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Small Cell Lung Cancer, Pancreatic Cancer, Head and Neck Cancer, Gastric Cancer, Esophageal Cancer
Interventions: Topotecan and pegylated doxorubicin; Drug
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Diabetes, Diabetic Foot, Diabetic Foot Ulcer, Diabetic Wound
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 6
States / cities: San Francisco, California • Stanford, California • Miami, Florida + 3 more

Conditions: Hyperandrogenism, Polycystic Ovary Syndrome, Puberty
Interventions: Micronized progesterone, Spironolactone, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 10 Years to 17 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Head and Neck Cancer
Interventions: gene expression analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis, immunohistochemistry staining method, needle biopsy; Genetic · Other · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Diabetes Mellitus, Type 2
Interventions: Pyridoxamine Dihydrochloride, placebo; Dietary Supplement · Drug
Lead sponsor: Columbia University; Other
Eligibility: 65 Years and older · Female only
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Congenital Adrenal Hyperplasia
Interventions: Hydrocortisone; Drug
Lead sponsor: Neurocrine UK Limited; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Polycystic Ovary Syndrome (PCOS)
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 14 Years to 40 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Thyroid Nodule, Thyroid Goiter, Ablation
Interventions: nPulse Vybrance Percutaneous Electrode System; Device
Lead sponsor: Pulse Biosciences, Inc.; Industry
Eligibility: 22 Years to 80 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Sarasota, Florida • New York, New York

Conditions: PreDiabetes, Type 2 Diabetes Mellitus
Interventions: High-effort session, Low-effort session, Control; Behavioral
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 75 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Polycystic Ovary Syndrome
Interventions: Cinnamon Extract, Placebo; Drug · Dietary Supplement
Lead sponsor: Rogerio A. Lobo; Other
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes Mellitus
Interventions: Not listed
Lead sponsor: Cook County Health; Government
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Obesity, Type 2 Diabetes, Metabolic Syndrome
Interventions: Not listed
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: insulin detemir, insulin glargine, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 28
States / cities: Anaheim, California • Huntington Beach, California • Inglewood, California + 24 more

Conditions: Type 1 Diabetes
Interventions: Insupatch, Continuous glucose sensor; Device
Lead sponsor: Yale University; Other
Eligibility: 8 Years to 44 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Overweight, Blood Pressure, Diabetes Mellitus, Type 2
Interventions: Plant-based diet, Control Group; Dietary Supplement
Lead sponsor: Physicians Committee for Responsible Medicine; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Diabetes, Pregnancy
Interventions: Insulin drip; Procedure
Lead sponsor: WellSpan Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: York, Pennsylvania

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin glargine, 300 units per milliliter (U/mL), Background therapy: Rapid Acting meal time insulin analogs (Humalog, Novolog or Apidra); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: West Des Moines, Iowa • Houston, Texas • Bridgeport, West Virginia

Conditions: Recurrent Ovarian Carcinoma
Interventions: Behavioral Intervention, Electronic Health Record Review, Interview, Survey Administration; Behavioral · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Metastatic Pancreatic Cancer
Interventions: Galunisertib, Durvalumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: Scottsdale, Arizona • New York, New York • Nashville, Tennessee

Conditions: Coronary Artery Disease, Hypertension, Dyslipidemia, Diabetes
Interventions: magnesium L-lactate; Drug
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Gastric Cancer, Gastric Adenocarcinoma, Gastric (Stomach) Cancer, Gastroesophageal Adenocarcinoma, Gastroesophageal Cancer (GC), Gastroesophageal Junction (GEJ) Adenocarcinoma, Gastroesophageal Junction (GEJ) Cancer, Gastrointestinal Cancer Metastatic, Gastrointestinal Adenocarcinoma, Gastrointestinal Cancers, Colorectal (Colon or Rectal) Cancer, Pancreatic Cancer, CDH17-positive Advanced Solid Tumors, Advanced Gastric Cancer
Interventions: BHB810; Drug
Lead sponsor: BigHat Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Duarte, California • Santa Monica, California • Fairfax, Virginia

Conditions: Schizophrenia, Schizoaffective Disorder, Type 2 Diabetes Mellitus, Hyperglycemia
Interventions: risperidone, olanzapine, quetiapine, ziprasidone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 2
States / cities: St Louis, Missouri

Conditions: Diabetes Mellitus, Type 2
Interventions: vildagliptin; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 345 participants
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Search by objective public record fields.

T1 Diabetes Hypoglycemia Prevention Pilot

Doxil Topotecan Doublet Cancer Study

C-myc Biomarker Study for Diabetic Foot Ulcers

Hyperandrogenemia and Altered Day-night LH Pulse Patterns

Genetic Analysis in Diagnosing Thyroid Cancer in Patients With Thyroid Nodules

Advanced Glycation Endproducts and Bone Material Strength in T2D Treated With Pyridoxamine

A Study of the Efficacy, Safety and Tolerability of Chronocort in Treating CAH

Blood Vessel Function in Adolescents and Women With Polycystic Ovary Syndrome

Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System

Is the Degree of Perceived Effort During Resistance Exercise Important for Improvements in Blood Glucose

Cinnamon Extract on Menstrual Cycles in PolyCystic Ovary Syndrome (PCOS)

Characteristics of Non Diabetic Hyperglycemic Inpatients

Evaluation of Intra-Abdominal Fat in Patients With Type 2 Diabetes Using a Non-Invasive Method

Safety and Efficacy of Insulin Detemir Plus Insulin Aspart Against Insulin Glargine Plus Insulin Aspart as Mealtime Insulin in Type 1 Diabetes

Warming up to Sensors: Does Site Warming Improve Continuous Glucose Monitor Performance?

A Nutritional Intervention in Police Officers

A Comparison of Insulin Drip Protocols in Labor: A Randomized Trial

Evaluation of Virtual Versus Traditional Study Conducted in a Group Pilot Study in Adult Patients With Type 1 Diabetes Mellitus (eStudy)

Helping Ovarian Cancer Patients Cope With Their Illness (HOPE)

A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer

The Use of Magnesium to Improve Blood Pressure, Cholesterol, and Glucose Control

Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma

Glucose and Lipid Metabolism on Antipsychotic Medication

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes